Treatment Strategies in Endogenous Fungal Endophthalmitis - Scorecard - MDSpire

Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

  • By

  • Arthi Venkat, MD, MS

  • Eleanor M. Burton, MD

  • January 1, 2026

  • 7 min

Share

Clinical Scorecard: Treatment Strategies in Endogenous Fungal Endophthalmitis

At a Glance

CategoryDetail
ConditionEndogenous Fungal Endophthalmitis (EFE)
Key MechanismsHematogenous dissemination of infectious nidus to the choroid.
Target PopulationPatients with culture-proven or clinically diagnosed EFE, particularly those with malignancy, intravenous drug use, and immunosuppression.
Care SettingMulticenter academic institutions.

Key Highlights

  • Fungal and bacterial organisms each account for roughly half of EFE cases.
  • Systemic fluconazole or voriconazole recommended for all patients with adjunctive intravitreal antifungals for severe cases.
  • 72% of eyes received combination systemic and intravitreal antifungals in recent studies.
  • Regional practice patterns show significant variation in initial therapy selection.
  • Systemic culture positivity influences the choice of initial therapy.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on culture-proven or clinically diagnosed EFE.

Management

  • Systemic fluconazole or voriconazole recommended; adjunctive intravitreal antifungals for macular involvement or vitritis.

Monitoring & Follow-up

  • Monitor for visual acuity outcomes and systemic markers of disease.

Risks

  • Potential for variation in treatment strategies and outcomes based on geographic region.

Patient & Prescribing Data

Patients with endogenous fungal endophthalmitis, particularly those with systemic infections.

Oral fluconazole and voriconazole achieve high bioavailability; IV loading doses may achieve steady-state concentrations more rapidly.

Clinical Best Practices

  • Consider a multidisciplinary approach to optimize patient outcomes.
  • Evaluate systemic markers of disease when choosing initial therapy.
  • Be aware of regional differences in treatment practices.

Related Resources & Content

Original Source(s)

Treatment Strategies in Endogenous Fungal Endophthalmitis

  • by Arthi Venkat, MD, MS, Eleanor M. Burton, MD

  • January 1, 2026

Related Content

Reflections from ASRS

Upfront: Monthly reflection by Editor in Chief Diana V. Do, MD.

Herpetic Eye Disease Is Not a Single Event

Joseph P. Shovlin, OD, FAAO, reviewed diagnosis, management, and emerging evidence related to chronic herpetic eye disease prevention at Optometry's Meeting 2026.

New Tools for Imaging Retinal Inflammation

At ARVO 2026, Ethan A. Rossi, PhD, presented data on multimodal AOSLO imaging of immune cells in the living eye.